RhumbLine Advisers’s Palisade Bio PALI Stock Holding History

RhumbLine Advisers’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$336K	Buy	+160,773	New	+$316K	﹤0.01%	2999
2015 Q2	–	Hold	0	–	-$104K	–	3071
2015 Q1	–	Hold	0	–	–	–	2949
2014 Q4	–	Hold	0	–	–	–	2942
2014 Q3	–	Hold	0	–	–	–	2887
2014 Q2	–	Hold	0	–	–	–	2893

Other funds holding PALI

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

RhumbLine Advisers's PALI Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Palisade Bio (PALI) in Q2 2026: 160,773 shares worth $336K. The stake represents ﹤0.01% of the portfolio and ranks #2999 among its holdings.

124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

RhumbLine Advisers held 160,773 shares of Palisade Bio worth $336K as of Q2 2026.
Palisade Bio was a new RhumbLine Advisers position in Q2 2026.
Palisade Bio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2999 holding.
124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.